Key Takeaways:
- European regulators recommend approval of Wegovy 7.2mg in a convenient single-dose pen format
- The high-dose formulation delivered 20.7% average weight loss in clinical trials
- European launch expected in Q3 2026, following successful US rollout as Wegovy HD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization of Wegovy 7.2mg in a single-dose pen for people living with obesity, Novo Nordisk announced on May 22, 2026. This milestone brings European patients one step closer to accessing the most potent obesity treatment available in a dramatically more convenient format.
European Approval Could Transform Treatment Convenience
Wegovy 7.2mg is already available in the EU for adults with obesity, dosed as three injections of 2.4mg, and is based on results from the STEP UP trial program. The new single-dose pen format represents a significant improvement in convenience and patient experience.
In the STEP UP trial, semaglutide 7.2mg injected once weekly demonstrated 20.7% mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. For context, this represents the highest weight loss results achieved by any FDA-approved obesity medication to date.
Although 7.2mg Wegovy is already approved in Europe, this is given as three separate injections of 2.4mg. The single-dose pen of 7.2mg, which is already marketed in the US and UK, will provide an easier dosing option for patients who previously had to manage multiple injections weekly.
The convenience factor cannot be overstated. Moving from three separate injections to one streamlines the treatment process, reduces injection site rotation complexity, and makes adherence more manageable for busy lifestyles.
US Success Story Points to European Potential
Wegovy 7.2mg in the single-dose pen is already approved in the US and UK. In the US, Wegovy 7.2mg is launched under the brand name Wegovy HD. The American launch has demonstrated strong patient demand for higher-dose options.
The US Food and Drug Administration approved the medicine in March 2026 after trial data showed an average weight loss of nearly 21% over 72 weeks. Wegovy HD is priced at $399 for cash-paying patients, while commercially insured patients may pay as low as $25 per month.
The US launch has exceeded expectations, with Novo Nordisk reporting robust prescription numbers in the first quarter of availability. This success suggests strong European demand when the single-dose pen becomes available. Early reports from American users highlight the convenience factor as a major quality-of-life improvement over previous multi-injection protocols.
Healthcare providers in the US have noted improved patient compliance rates with the single-dose format, which translates to better long-term outcomes for weight management.
Clinical Evidence Behind the Recommendation
The STEP UP and STEP UP T2D phase 3 trials investigated the efficacy and safety of injectable semaglutide 7.2mg in people with obesity without or with type 2 diabetes. The 72-week STEP UP trial evaluated the efficacy and safety of injectable semaglutide 7.2mg compared to semaglutide 2.4mg and placebo as an adjunct to lifestyle intervention. The trial included approximately 1,400 adults with obesity.
According to analysis presented at the 2026 European Congress on Obesity, early Wegovy responders in the pivotal STEP UP trial lost 27.7% of their weight from baseline, on average, at week 72 while taking a 7.2mg dose weekly. Researchers deemed patients early responders if they lost at least 15% of their body weight after 24 weeks of treatment.
In the STEP UP T2D trial, in participants with obesity and type 2 diabetes, semaglutide 7.2mg demonstrated a mean weight loss of 14.1%, showing effectiveness across different patient populations. This data is particularly important for the significant population managing both obesity and diabetes simultaneously.
The safety profile remained consistent with lower doses, with gastrointestinal side effects being the most common reported issues. Most participants who experienced side effects found them manageable and transient.
Regulatory Timeline and Market Access
The guidance will now pass to the European Commission for a final decision, though it is expected that both the pill and high-dose version will be approved. Novo Nordisk expects to launch Wegovy 7.2mg in a single-dose pen in the EU in Q3 2026.
The CHMP recommendation is particularly significant because it comes alongside a separate positive opinion for Wegovy pill, making this a landmark month for European obesity treatment options. If the European Commission follows the CHMP's recommendation, then oral Wegovy will become the first glucagon-like peptide receptor agonist pill approved for weight management in Europe.
This dual approval represents a comprehensive expansion of GLP-1 medication options for European patients, offering both convenience improvements and new delivery methods to suit different preferences and medical needs.
Global Competitive Landscape
Novo Nordisk presents new data on Wegovy as the company continues to battle for market share with competitor Eli Lilly in the burgeoning obesity field. Following a tough year, the Danish pharma's Q1 results could allude to a potential turn in fortunes.
The timing is crucial as competition intensifies in the global obesity market. With Eli Lilly's Foundayo (orforglipron) and retatrutide advancing through trials, Novo Nordisk's expansion of Wegovy options helps maintain its competitive position. This competitive environment ultimately benefits patients by driving innovation and potentially improving access.
The high-dose single-pen format gives Novo Nordisk a differentiated offering that combines maximum efficacy with optimal convenience, potentially setting a new standard for obesity treatment delivery.
What This Means for You
If you're in Europe and currently using the three-injection 2.4mg Wegovy protocol, the single-dose 7.2mg pen could dramatically simplify your treatment routine while potentially delivering better weight loss results. The convenience factor alone makes this a significant development for people who want the effectiveness of high-dose treatment without the complexity of multiple injections.
For those considering GLP-1 treatment, this approval expands your future options significantly. You'll soon have access to the highest-dose GLP-1 treatment available in the most convenient injectable format. If you're exploring treatment options, consider discussing the upcoming high-dose option with healthcare providers as you plan your treatment approach.
If you're currently working with a provider or looking for GLP-1 clinics, this is an excellent time to discuss timing and preparation for when the single-dose format becomes available. Many providers are already preparing protocols for transitioning eligible patients to the more convenient option once it launches.
Sources
- Novo Nordisk Press Release - CHMP recommends EU approval of Wegovy 7.2mg single-dose pen
- Pharmaceutical Technology - EMA recommends approvals for both oral and high-dose pen versions
- Clinical Trials Arena - High-dose Wegovy shows 27.7% weight loss in early responders
- HealthCare Middle East & Africa - EMA panel recommends approval for new Wegovy single-dose pen